TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
TLR ligands that mimic pathogen associated molecular patterns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as Imiquimod and Resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODN) that bind to TLR9. This study was aimed at comparing CpG ODN and R-848 for their potential use as vaccine adjuvants and to determine whether there are additive or synergistic effects when they are used together. Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses.
Weeratna
Risini D
RD
Coley Pharmaceutical Group, Suite 200, Ottawa, ON, Canada K2K 3A2. rweeratna@coleypharma.com
Makinen
Shawn R
SR
McCluskie
Michael J
MJ
Davis
Heather L
HL
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D005260:Female; D006508:Hepatitis Antibodies / Q000032:analysis / Q000096:biosynthesis; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D007093:Imidazoles / Q000494:pharmacology*; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007114:Immunization; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D051193:Toll-Like Receptors / Q000819:agonists*
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D016207:Cytokines; D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens; D007093:Imidazoles; D009838:Oligodeoxyribonucleotides; D051193:Toll-Like Receptors; D007371:Interferon-gamma; C402365:resiquimod